|
 |
 |
 |
 |
 |
|
Let us help you find the right supplier for
Antineoplastic Agent |
|
|
|
|
|
 Antineoplastic Agent |
 Bicalutamide | Carboplatin | Cisplatin |
| Doxorubicin | Etoposide | Methotrexate |
| Vincristine |
|
Medicare Remedies Private Limited ( India) Company Profile: Established in 2007 we are a leading manufacturer of letrozole tablets, capcetabine tablets, gefitinib tablets, gefticare- gefitinib 250mg tablets, antineoplastic agent, pharmaceutical formulations, pharmaceutical tablets Contact Details:
Zunan Commerce & Industrial Co. Limited ( China) Company Profile: Authorized dealer of all kinds of antineoplastic agents, ceftriaxone sodium and cephalosporin antibiotics. Contact Details:
Mediline Pharmaceutical India Private Limited ( India) Company Profile: Engaged in trading of antineoplastic agents. Contact Details:
Naik Pharmaceutical Co. ( India) Company Profile: Manufacturer of antipyretic analgesics, antiparasitic agents, cardiovascular agents and antineoplastic agents. Contact Details:
 Pharma Vision 2000 ( India) Company Profile: Supplying and manufacturing pharmaceutical injectables , 200mg voriconazole tablets, 250mg gefitinib tablet, 2 mg injection, anti cancer tablet, antifolate antineoplastic agents injection and pharmaceutical injection used for cancer treatment. Contact Details:
|
 |
|
Antineoplastic agents are specifically used for restricting the growth of neoplasms, keeping a check on the maturation and development of malignant cell in the human body. These drugs are quite different from the other alkylating agents because they are mono functional in their nature and does not cross link cellular macromolecules. There are so many types of antineoplastic agents used for treating cancers such as carboplatin, cisplatin, cyclophosphamide, doxorubicin, methotrexate, flurorouracil and paclitaxel. These agents travel and kill cancer cells growing in the interiors of the human body. Antineoplastic agents industry sizes around US$ 16 billion, which is expected to reach US $ 22 billion by the end of 2009.